[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spasticity-with-multiple-sclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spasticity-with-multiple-sclerosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100628836","classification-of-upper-and-lower-limb-spasticity-patterns-and-their-impact-on-quality-of-life-in-patients-with-multiple-sclerosis-100628836",false,"NCT07466823","Classification of Upper and Lower Limb Spasticity Patterns and Their Impact on Quality of Life in Patients With Multiple Sclerosis","Inclusion Criteria:\n\n* Diagnosis of multiple sclerosis according to the 2024 McDonald criteria\n* Age ≥ 18 years\n* Presence of clinical spasticity defined as Modified Ashworth Scale score ≥ 1 in at least one joint\n* Ability to understand study procedures and provide informed consent\n* Absence of significant cognitive impairment\n\nExclusion Criteria:\n\n* Presence of orthopedic, rheumatologic, or neurological conditions affecting movement other than multiple sclerosis\n* Botulinum toxin type A injection within the previous 3 months\n* Previous surgical treatment for upper extremity spasticity\n* Bone deformities affecting the upper extremity\n* Inability or unwillingness to provide informed consent\n* Presence of cognitive impairment","ALL","18 Years",{"count":18,"type":19},75,"ESTIMATED","OBSERVATIONAL","Multiple sclerosis (MS) is a chronic neurological disease frequently associated with spasticity, which may lead to functional limitations and reduced quality of life. Although spasticity is common in MS, detailed descriptions of upper and lower extremity spasticity patterns are limited. A better understanding of spasticity patterns may help improve individualized rehabilitation and treatment planning.\n\nThe aim of this study is to classify upper and lower extremity spasticity patterns in patients with multiple sclerosis and to investigate their association with quality of life. Adult patients with MS and clinical spasticity will be recruited from a tertiary care outpatient clinic. Spasticity will be evaluated using the Modified Ashworth Scale, and extremity postures will be recorded to define spasticity patterns. Functional performance will be assessed using the Timed 25-Foot Walk Test and the 9-Hole Peg Test. The impact of spasticity on quality of life will be evaluated using the Patient-Reported Impact of Spasticity Measure (PRISM).\n\nThis prospective cross-sectional study is designed to provide a systematic description of spasticity patterns in patients with multiple sclerosis and to examine their relationship with functional outcomes and quality of life.",[23,24,25],"Multiple Sclerosis","Spasticity","Spasticity With Multiple Sclerosis",[27,24,28,29,30,31],"Multiple sclerosis","Spasticity patterns","PRISM","Upper extremity spasticity","Lower extremity spasticity","RECRUITING","2026-03-29",{"date":35,"type":36},"2026-04-02","ACTUAL",{"date":38,"type":36},"2026-01-01",{"date":40,"type":19},"2026-07-01",{"name":42,"class":43},"Marmara University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100608487","at-home-use-of-stimulation-suits-for-managing-ms-symptoms-100608487","NCT07202195","At Home Use of Stimulation Suits for Managing MS Symptoms","Home-Based Neuromodulation Suits for Reducing Spasticity and Ataxia in Multiple Sclerosis: A Multi-center RCT","HANDS-MS","Inclusion Criteria:\n\n* Eligible participants must have ataxia or spasticity alongside impairments in upper or lower extremity physical function. MAS score ≥ 1 will be used as an inclusion criterion to determine the presence of spasticity. SARA score ≥ 4 will be used as an inclusion criterion to determine the presence of ataxia. Note: one of the two criteria (MAS score or SARA score) must be fulfilled for a pwMS to be eligible.\n* The patient must have the cognitive abilities to understand instructions and to be able to complete the questionnaires adequately\n* Diagnosis of multiple sclerosis.\n\nExclusion Criteria:\n\n* Implanted devices (like pacemaker, Baclofen pump, neurostimulator, defibrillator, shunts, ECG equipment, electronic life support, high frequency operation equipment )\n* Change in disease modifying treatment within the last 3 months\n* Use of Botuline Toxine A within the last 3months\n* Recent relapse within the last 3 months\n* Acute musculoskeletal problems that hinder the test performance,\n* Pregnancy\n* Sizes bigger than 3XL (triple eXtra Large)\n* Skin eruptions and\u002For skin areas in the stimulation zone that are swollen, infected or inflamed.",{"count":54,"type":19},70,"INTERVENTIONAL",[57],"NA","This study is being carried out at Multiple Sclerosis (MS) centers to evaluate whether a full-body stimulation suit at home can help people with Multiple Sclerosis (pwMS) reduce symptoms like spasticity (muscle stiffness) and ataxia (poor coordination), and improve daily functioning.\n\nCan pwMS who experience spasticity or ataxia benefit from using a stimulation suit for 6 weeks?\n\nResearchers will compare two groups: an intervention group (who will use the suit) and a control group (who will not use the suit).\n\nParticipants in the intervention group will:\n\n* Wear the suit for 6 weeks in total every day or every other day (1 week during their MS center admission and 5 weeks at home).\n* Receive their usual care in addition to wearing the suit.\n* Undergo clinical tests at the MS center after 1 week and 6 weeks of stimulation.\n\nParticipants in the control group will:\n\n* Receive their usual care.\n* Undergo clincial tests at the same time points as the other group.",[23,60,25,61,62,63,24,64],"MS (Multiple Sclerosis)","Ataxia - Other","Ataxia, Cerebellar","Ataxia, Motor","Home Based Care",[66,67,68,69,70,71,72,73,74],"ataxia","spasticity","multiple sclerosis","MS","neuromodulation suit","stimulation suit","exopluse molli suit","home-based rehabilitation","symptom management","2026-02-04",{"date":77,"type":36},"2026-02-06",{"date":79,"type":19},"2026-03",{"date":81,"type":19},"2027-09",{"name":83,"class":43},"Daphne Kos",2,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":95,"conditions":96,"keywords":102,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":44},"100601317","analysis-of-balance-disorders-after-botulinum-toxin-treatment-in-the-rectus-femoris-in-patients-with-a-stiff-knee-gait-100601317","NCT07108920","Analysis of Balance Disorders After Botulinum Toxin Treatment in the Rectus Femoris in Patients With a Stiff Knee Gait","Analysis of Balance Disorders After Botulinum Toxin Treatment in the Rectus Femoris in Patients With a Stiff Knee Gait: What About the Risk of Falls?","FEMFALLTOX","Inclusion Criteria:\n\n* Patient with a stif knee gait (SKG) after a stroke, a post-traumatic cerebral lesion or a multiple sclerosis.\n* If the patient had a stroke, it happened at least 4 month ago (before the inclusion).\n* The patient has a rectus femoris spasticity ≥ 1 on the modified Ashworth Scale with the hip in extension position.\n* A quadricipital muscular force ≥ 2\u002F5 (MRC Scale)\n* The patient didn't receive any botulinum toxin injection during the 3 previous months\n* No modification of any anti-spastic medication during the inclusion in the actual month (Baclofène, Dantrolène).\n* No neurosurgical intervention or ligamentoplasty of the quadricipital ligament during the 6 previous months.\n* No recent knee traumatism with knee instability during the 6 previous weeks.\n\nExclusion Criteria:\n\n* Other comorbidities invalidating the fonctionnal tests necessary for the study like : decompensated cardiac insufficiency, unstable respiratory insufficiency, coagulation troubles, neurocognitive impairments inhibiting the comprehension of isocinetical tests.\n* Patient without severe phasic trouble inhibiting the patient's ability to answer the evaluation scales.\n* Sensory lesions inhibiting the possibility to evaluate the walk : visual impairment, major proprioception impairment, or cerebellar ataxia.\n* Severe muscular deficit : genetic myopathy, psychomotric desadaptation syndrom\n* Absolute contraindication to botulinum toxin injections : urinary tract infection ; current treatment by aminoglycosidic antibiotics, severe myasthenia, urine retention in patient who can't receive a urinary catheter.\n* Patient with cognitive troubles compromitting the understanding and the realization of the study.",{"count":94,"type":19},15,"Patients who suffered a stroke, cranial traumatism, medullar lesions or multiple sclerosis can present spastic muscular complications, which is particularly impairing if it concerns muscles of the leg. Muscular spastic complications of the legs can alter significantly the ability to walk because it clinically manifests itself by a stiffness of the leg, thus generating a complication called \"Stif Knee Gait\" (SKG). It means that the femoro-patello-tibial articulation cannot be mobilized as it should because it stays spastic instead of being mobile.\n\nHowever, it remains possible to treat this kind of medical condition by using Botulinum toxin injections in the target muscle, in particular the rectus femoris (which is part of the quadriceps).\n\nAs a reminder, botulinum toxin, sold under the international common denomination \"Botox®\", is a neurotoxin of 150 kDa produced by the bacteria \"Clostridium Botulinum\" and is the most powerful natural poison known to humankind, with its DL50 between 1 and 2 nanogramms \u002F kg in humans. This toxin works by entering the neuro-muscular synaptic junctions and by linking itself to a proteic complex called SNARE. The link between the toxin and the SNARE complex inhibits the fusion of the acetylcholinergic synaptic vesicles with the plasmic membrane of the pre-synaptic axone. The Botox® blocks the exocytosis of the acetycholin (Ach) vesicle in the inter-synaptic space at the neuro-muscular junction and blocks the nervous transmission, thus generating muscular flaccid paralysis. This kind of intoxication is caused directly by an infection by Clostridium Botulinum and is called Botulism. It manifests itself clinically by flaccid paralysis, swelling, diarrhea tiredness, respiratory failure, vomiting etc…\n\nDespite its highly toxic properties, Botox® can be used as a therapeutic tool against number of medical conditions (strabismus, hyperhidrosis, migraines etc…) and even as a cosmetic tool (anti face-wrinkles). It can be used against spastic muscular paralysis, especially like the ones encountered in the patients of this study.\n\nThe current Standard Of Care (SOC) against SKG is to inject Botox into the rectus femoris in order to counter its spasticity. It has been shown to upgrade the walking ability of SKG patients by enhancing the leg kinetics. More precisely, it has been shown to improve the fluidity of the movement of the spastic leg in SKG patients, especially the knee flexion. However, the rectus femoris' contractility remains necessary to be able to stand up statically and to stay balanced during the walk and everyday-activity and the myorelaxant properties of Botox® may be problematic and alter the leg biomechanics despite its utility. To this day, no study has been published to compare the static and dynamic balance troubles before and after Botox injections in the rectus femoris.\n\nThe medical bibliography does not report any augmentation of the risk of fall in the case of Botox injection in the rectus femoris. However, we consider the hypothesis along which those injections can enhance the risk of fall. Therefore, we decided to conduct a monocentric, prospective observational clinical study to compare the state of the static and dynamic balance before and after Botox injections in the rectus femoris (in SKG patients) by using balance scores.\n\nIn order to complete this objective, we compared the following parameters before and after the Botox injection in SKG patients :\n\n* Time Up and Go test(in seconds) : primary evaluation criteria\n* Berg Balance Scale (BBS) : secondary evaluation criteria\n* Stair climb and descent time test (SCT) : secondary evaluation criteria.\n* Number of falls.",[97,98,99,100,101,25],"Botulinum Toxin Injection","Stiff Knee Gait","Fall Risk","Rectus Femoris Muscle","Botox Injection",[103,104,105,106,107],"Botulinum toxin injection","Rectus femoris","Balance troubles","Fall risk analysis","Stiff knee gait patients.","2025-09-19",{"date":110,"type":36},"2025-09-22",{"date":112,"type":19},"2025-10-01",{"date":114,"type":19},"2026-08-01",{"name":116,"class":43},"Hopital Nord Franche-Comte"]